FDA Office of New Drugs (correction)
Executive Summary
A chart outlining the new structure of the Office of New Drugs published in the June 27 issue of "The Pink Sheet" incorrectly reported the status of the division directors in the Office of Non-Prescription Products. Curtis Rosebraugh is acting director for the Division of Non-Prescription Clinical Evaluation, and Susan Johnson is acting director for the Division of Non-Prescription Regulation Development. An accompanying story also suggested that Robert Justice is the permanent director of the Division of Drug Oncology Products; he will serve on an acting basis...